Erschienen in:
12.10.2016 | Acute Myeloid Leukemias (H Erba, Section Editor)
Antibody-Based Treatment of Acute Myeloid Leukemia
verfasst von:
Phillip M. Garfin, Eric J. Feldman
Erschienen in:
Current Hematologic Malignancy Reports
|
Ausgabe 6/2016
Einloggen, um Zugang zu erhalten
Abstract
While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.